Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 10, 2013

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Thromboembolism
Interventions
DRUG

Apixaban

Specified dose on specified days

Trial Locations (27)

3052

Local Institution, Parkville

14080

Local Institution, Mexico City

15224

Children's Hopsital Of Pittsburgh Of UPMC, Pittsburgh

Children's Hospital Of Pittsburgh Of UPMC, Pittsburgh

17033

Penn State Hershey Children'S Hospital, Hershey

19104

Childrens Hospital Of Philadelphia, Philadelphia

20007

MedStar Georgetown University Hospital, Washington D.C.

20010

Childrens National Medical Center, Washington D.C.

27710

Duke University Medical Center, Durham

30322

Children's Healthcare Of Atlanta, Atlanta

40202

Kosair Charities Pediatric Clinical Research Unit, Louisville

43606

ProMedica Toledo Children's Hospital, Toledo

44260

Local Institution, Guadalajara

50309

Blank Childrens Hospital, Des Moines

52242

University of Iowa Hospitals and Clinics, Iowa City

52621

Local Institution, Ramat Gan

53226

Childrens Hospital Of Wisconsin, Milwaukee

64108

Children'S Mercy Hospital And Clinics, Kansas City

64460

Local Institution, Monterrey

92868

Children'S Hospital Of Orange County, Orange

72202-3591

Arkansas Children'S Hospital, Little Rock

06106

Connecticut Children's Medical Center, Hartford

08901

Saint Peter'S University Hospital, New Brunswick

T6G 1C9

University of Alberta - Edmonton Clinic Health Academy, Edmonton

L8S 4K1

Local Institution, Hamilton

M5G 1X8

The Hospital For Sick Children, Toronto

04530

Local Institution, Mexico City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT01707394 - Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder | Biotech Hunter | Biotech Hunter